Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tedizolid
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate Oral Formulations of Tedizolid Phosphate in Healthy Participants (MK-1986-043)
Details : Tedizolid Phosphate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 13, 2024
Lead Product(s) : Tedizolid
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tedizolid
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Compare Oral Formulations of Tedizolid Phosphate in Healthy Adults (MK-1986-044)
Details : Tedizolid Phosphate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 24, 2024
Lead Product(s) : Tedizolid
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tedizolid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Sun Pharma Introduces a Novel Treatment, STARIZO in India for Bacterial Skin Infections
Details : Starizo (tedizolid phosphate) is an oxazolidinone-class antibacterial drug indicated in adult and pediatric patients 12 years of age and older for acute bacterial skin and skin structure infections.
Product Name : Starizo
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 23, 2024
Lead Product(s) : Tedizolid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tedizolid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Hetero Gets CDSCO Panel Nod to Study Tedizolid Phosphate for Bacterial Skin Infections
Details : Tedizolid phosphate is an oxazolidinone-class antibacterial drug indicated in adult patients for the treatment of acute bacterial skin and skin structure infections.
Product Name : Tedizolid Phosphate-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 16, 2024
Lead Product(s) : Tedizolid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tedizolid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Voluntary Announcement - Tedizolid Phosphate for Injection Obtains Approval
Details : Tedizolid phosphate is an oxazolidinone-class antibacterial drug indicated in adult patients for the treatment of acute bacterial skin and skin structure infections.
Product Name : Tedizolid Phosphate-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 27, 2023
Lead Product(s) : Tedizolid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tedizolid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the initial term of the agreement, Nabriva was solely responsible for marketing, sales, and distribution of SIVEXTRO (Tedizolid Phosphate) in the United States through December 31, 2023. The amendment extends the agreement to December 31, 2026.
Product Name : Sivextro
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 05, 2022
Lead Product(s) : Tedizolid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Tedizolid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreement, Nabriva will procure SIVEXTRO from Merck & Co. Inc., Kenilworth, N.J., USA and be responsible for marketing, sales, and distribution of SIVEXTRO in the U.S. through December 31, 2023, with renewable three-year extensions...
Product Name : Sivextro
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 15, 2020
Lead Product(s) : Tedizolid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Tedizolid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Sivextro Approval Expanded to Include Pediatric Patients
Details : Sivextro (tedizolid phosphate) is an oxazolidinone-class antibacterial drug indicated in adult and pediatric patients 12 years of age and older for acute bacterial skin and skin structure infections.
Product Name : Sivextro
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 25, 2020
Lead Product(s) : Tedizolid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tedizolid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tedizolid Phosphate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Gram-Positive Bacterial Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 14, 2017
Lead Product(s) : Tedizolid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tedizolid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tedizolid Phosphate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Skin Diseases, Infectious.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 05, 2017
Lead Product(s) : Tedizolid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable